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Homeostasis in colonic epithelial cells is regulated by the
balance between proliferative activity and cell loss by
apoptosis. Because epithelial cells at the apex of colonic
crypts undergo apoptosis and proliferative activity is
usually restricted to the base of the crypts, it has been
proposed that the limited availability of growth factor-
signals at the upper portions of the crypts may trigger
apoptosis. In the present studies, we investigate the
mechanism of apoptosis mediated by growth factor
deprivation in colorectal carcinoma cells by delineating
the possible involvement of Bax and its subcellular
localization. We report that inhibition of epidermal
growth factor receptor (EGFR) tyrosine kinase activity
and downregulation of EGFR by anti-EGFR mAb 225
induces apoptosis in human colorectal carcinoma DiFi
and FET cells. Induction of apoptosis was preceded by
enhanced expression of newly synthesized Bax protein,
and required protein synthesis. In the mAb 225-treated
cells, Bax was redistributed from the cytosol to the
nucleus and subsequently, to the nuclear membranes. The
observed induction of Bax expression by mAb 225 was
not associated with p53 induction. However, mAb 225
treatment also triggered relocalization of p53 from the
cytosol to a nuclear membrane-bound form. Induction of
Bax and its redistribution to the nucleus of DiFi cells
during apoptosis was also demonstrated in response to
butyrate, a physiological relevant molecule in colonic
epithelial cells as it is the principal short-chain fatty acid
produced by bacterial fermentation of dietary fiber in
colonic epithelium. Using immunofluorescence and con-
focal microscopy, we observed that Bax is predominantly
localized in the cytosol, but during apoptosis it is
localized both inside and along the nuclear membrane.
Taken together, these findings suggest that apoptosis
induced by growth factor-deprivation or butyrate may
involve the subcellular redistribution of Bax in human
colorectal carcinoma cells.
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Introduction
Homeostasis in colonic epithelial cells is regulated by a
balance between proliferative activity at the base of the
crypt and cell loss at the apex of the crypt and in the
lumen (Gavrieli et al., 1992). Apoptosis is a
physiological mechanism of cell loss that is dependent
on both pre-existing proteins and de novo protein
synthesis (Reed 1997; Korsmeyer 1995; Boise et al.,
1995). Apoptosis appears to have an integral role in the
normal colon in vivo (Hockenbery et al., 1991;
Krajewski et al., 1994), and deregulation of apoptosis
may be involved in the development of colorectal
cancer (Bedi et al., 1995).
Recent studies have established the essential role of
growth factors that activate epidermal growth factor
receptors (EGFR) in stimulating proliferation of
colonic epithelium (Brattain et al., 1994). A number
of epithelial tumor cells with increased expression of
EGFR also produce its ligands, and therefore, leading
to enhanced autocrine growth stimulation (Kumar and
Mendelsohn 1991; Van de Vijver et al., 1991; Atlas et
al., 1992). EGFR and TGF-alpha are expressed in
human colorectal carcinomas (Malden et al., 1989) and
in a number of colorectal carcinoma-derived human
cell lines (Coey et al., 1986; Markowitz et al., 1990;
Untawalwe et al., 1993). In recent years, approaches
involving interference with and/or blocking of EGFR-
mediated autocrine growth stimulation by anti-EGFR
mAbs have been the subject of active investigation in
an eort to control cell proliferation (Mendelsohn
1990). Furthermore, growth factors may also contri-
bute towards cell survival since growth factor with-
drawal can lead to apoptosis (Oltvai et al., 1993; White
1996). There are numerous examples demonstrating
that EGF can prevent apoptosis in response to a wide
variety of stimuli (Coles et al., 1993; Luciano et al.,
1994; Nakajima et al., 1994; Fabregat et al., 1996;
Garcia-Lloret et al., 1996), and inhibition of EGFR
expression can induce apoptosis (Englert et al., 1995).
Since activation of EGFRs may be involved in
stimulating colonic epithelium proliferation and in
antagonizing apoptosis, one potential mechanism to
suppress colorectal cancer may include modulation of
apoptotic pathway(s) by inhibiting EGFR using anti-
EGFR mAbs.
The occurrence of apoptosis is a highly regulated
process. One important regulator of apoptosis is Bcl-
2, a 26 kDa protein that protects cells against
apoptosis in a variety of experimental systems
(Korsmeyer 1995; Mandal and Kumar, 1996; Mandal
et al., 1996). Bcl-2 protein is primarily localized to the
nuclear envelope, the endoplasmic reticulum, and the
outer mitochondrial membranes (Krajewski et al.,
1993; Lithgow et al., 1994). A number of Bcl-2
homologues have been identified, including Bcl-XL
which suppresses apoptosis (Boise et al., 1993) and
Bax which promotes apoptosis (Oltvai et al., 1993).
Since Bcl-2 can influence Ca++ across membranes
(Bay et al., 1993; Lam et al., 1994), it has been also
proposed that Bcl-2 or its family members may be
involved in tracking of ions (Reed 1994). In an
analysis of the three-dimensional structure of Bcl-XL,
Muchmore et al. (1996) demonstrated significant
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similarity with the pore-forming domains of bacterial
toxins and proposed that Bcl-XL or its family
members may be involved in regulating ion-channels
across membranes. In support of this proposal,
Schendel et al. (1997) demonstrated the ability of
recombinant Bcl-2 to form ion channels using a
synthetic lipid bilayer-based assay.
Recent studies suggest that cells derived from a
variety of human cancers, including colorectal (Bedi et
al., 1995), have a decreased capacity to undergo
apoptosis in response to various physiological stimuli
(Carson and Ribeiro, 1993; Thompson 1995). Thus, a
defect in apoptosis may be involved in the aberrant
survival and/or development of colorectal cancer cells.
Colonic epithelial cells at the apex of crypts, where
apoptosis is active, display strong Bax immunoreactivity
(Krajewski et al., 1994). Bax forms homodimers and
also heterodimers with anti-apoptotic family members
such as Bcl-2, Bcl-XL, and Mcl-1 (Boise et al., 1995).
Current models suggest that the ratios of anti- to pro-
apoptotic proteins play a regulatory role in apoptosis
(Oltvai et al., 1993; Sedlak et al., 1995). Both Bax and
Bcl-2 appear to be regulated independently, as Bcl-2
overexpression does not aect Bax induction (Miyashita
et al., 1994). The overexpression of Bax has been shown
to accelerate apoptosis in response to a variety of
stimuli, including growth factor withdrawal (Oltvai et
al., 1993; Brady et al., 1996a).
Earlier we showed that inhibition of EGFR tyrosine
phosphorylation by anti-EGFR mAb 225 induces
apoptosis in DiFi human colorectal carcinoma cells
(Wu et al., 1995). In the present study, we investigate
the mechanism of EGFR-mediated apoptosis in color-
ectal carcinoma cells by delineating the involvement of
Bax. We report experiments utilizing mAb 225 against
the EGFR which blocks binding of ligand and prevents
ligand-induced activation of receptor tyrosine kinase
(Kawamoto et al., 1983). We demonstrate that mAb
225-induced apoptosis in colorectal cancer cells was
preceded by enhanced expression of newly synthesized
Bax protein, a redistribution of Bax from the cytosol to
the nucleus and subsequently to the nuclear mem-
branes. In addition, both induction and redistribution
of Bax in colorectal carcinoma cells was also
demonstrated by butyrate, a physiological relevant
molecule in colonic epithelium.
Results
MAb 225 induces apoptosis in colorectal carcinoma DiFi
and FET cells
Results in Figure 1A demonstrate that mAb 225
treatment of DiFi cells inhibited the constitutive
activation of EGFR (upper panel) and also reduced
EGFR expression (middle panel). As an internal
control, the lower portion of the EGFR blot was
reprobed with an unrelated anti-Ku80 mAb (lower
panel), and there was no eect of mAb 225 on the
expression of Ku80. The observed inhibition of EGFR-
signaling by mAb 225 was accompanied by induction
of apoptosis as determined by a quantitative ELISA-
based assay (Figure 1B). To quantitate apoptosis, DiFi
cells treated with or without mAb 225 were stained
with propidium iodide and analysed by FACS. MAb
treatment (24 h) of DiFi cells enhanced the percentage
of cells in the pre-Go apoptotic polulation by 36.9%
compared to control cells (Figure 1C). Treatment with
mAb 225 also caused a reduction in the viability of
DiFi cells by 45% compared to control cells in a time-
dependent manner (Figure 1D). These results are
Figure 1 Inhibition of EGFR by mAb 225 induces apoptosis in human colorectal carcinoma cells. (A) DiFi cells were cultured with
20 nM mAb 225 for dierent times, and cell lysates (30 mg protein) were analysed by SDS–PAGE and immunoblotted with an anti-
phosphotyrosine mAb PY-20 (upper panel) and then reprobed with an anti-EGFR mAb (middle panel). As an internal control, the
lower part of the EGFR blot was immunoblotted with an unrelated anti-Ku80 mAb (lower panel). (B) Cell lysates from DiFi cells
treated with 20 nM mAb 225 were quantitatively assayed for the induction of apoptosis using the ELISA assay (C) FACS profile of
DiFi cells treated with 20 nM mAb 225 for 24 h. Bar in mAb treated cells shows apoptotic cells. (D) DiFi cells were treated with
20 nM mAb 225 for dierent times and cellular viability was determined by trypan blue staining (n=3). Results shown are
representative of three or more independent experiments
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consistent with our earlier report that mAb 225-inhibits
the growth of DiFi cells (Wu et al., 1995).
The observed induction of apoptosis by anti-EGFR
mAb 225 was not a restricted phenomenon in DiFi
cells with high EGFR (1.5 – 26106/cell) (Olive et al.,
1993), as downregulation of EGFR by mAb 225 also
induces apoptosis in another colorectal carcinoma
FET cells (Figure 2A, upper two blots) which have
low EGF binding sites [6.06103, high anity;
4.266104, low anity (Huang et al., 1992)]. Immuno-
blotting of the lower portion of the EGFR blot was
with an anti-poly(ADP-ribose)polymerase (PARP)
mAb revealed its proteolytic cleavage into 85 kD
fragment (Figure 2A). The observed PARP cleavage
was a specific apoptotic eect of mAb 225, as
reprobing the PARP blot with an unrelated anti-
Ku80 mAb indicated that there was no eect of mAb
225 on Ku80 expression (Figure 2A, lower blot).
Induction of apoptosis in FET cells by mAb 225 was
also confirmed by DNA fragmentation (Figure 2B),
and 26% increased appearance of pre-Go apoptotic
polulation in cells treated for 24 h with mAb 225,
compared to untreated cells (Figure 2C). Consistent
with these results, mAb 225 also reduced the viability
of FET cells by 41% compared to control cells in a
time-dependent manner (Figure 2D).
Mab 225-induced apoptosis is accompanied by increased
expression of Bax
Since apoptosis is regulated by the ratios between pro-
and anti-apoptotic gene product, we hypothesized that
mAb 225-induced apoptosis may involve Bax and thus
modulate the ratio of Bax to Bcl-2 in favor of cell death.
Therefore, we examined the eect of mAb 225 on the
expression of Bax in DiFi cells. As shown in Figure 3A,
treatment of DiFi cells with mAb 225 induced increased
levels of Bax in a time-dependent manner starting at 3 h
post-treatment. As an internal control, the upper
portion of the Bax blot was blotted with an unrelated
mAb against heat-shock protein-70 (Figure 3A).
Quantitation of Bax induction in relation to HSP-70
expression indicated that there was seven fold increase
in the expression of Bax in cells treated with mAb 225
for 12 h, compared to untreated cells (Figure 3B). To
further characterize the induction of Bax in mAb 225-
treated cells, we examined the synthesis of Bax protein.
DiFi cells were labeled with 35S-methionine for the last
3 h before preparing cell extracts. MAb 225 treatment
resulted in the increased expression of newly synthesized
Bax within 3 h of treatment (Figure 3C).
Since apoptosis in other systems has been shown to
be protein synthesis-dependent (Brady et al. 1996b), we
Figure 2 (A) FET cells were cultured with 20 nM mAb 225 for dierent times, and cell lysates (30 mg protein) were analysed by
SDS–PAGE and immunoblotted with an anti-phosphotyrosine mAb PY-20 (upper panel) and then reprobed with an anti-EGFR
mAb (second panel). As an internal control, the lower part of the EGFR blot was immunoblotted with an anti-PARP mAb (third
panel) and then reprobed with an unrelated anti-Ku80 mAb (fourth panel). (B) Induction of DNA-fragmentation in FET cells by
20 nM mAb 225. (C) FACS profile of DiFi cells treated with 20 nM mAb 225 for 24 h. Bar in mAb treated cells shows apoptotic
cells. (D) DiFi cells were treated with 20 nM mAb 225 for dierent times and cellular viability was determined by trypan blue
staining (n=3). Results shown are representative of three or more independent experiments
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investigated whether mAb 225-mediated apoptosis
require on-going protein synthesis. DiFi cells were
treated with mAb 225 in the presence or absence of
cycloheximide, and cell extracts were assayed for the
induction of apoptosis. As shown in Figure 3D,
exposure of DiFi cells to cycloheximide prevented
mAb 225-induced apoptosis. As expected, cyclohex-
imide treatment of DiFi cells also prevented the mAb
225-induced increase in Bax expression (data not
shown).
MAb 225 and butyrate trigger nuclear translocation of
Bax
Bcl-2 family members have been proposed to be
involved in membrane functions (Reed 1994; Schendel
et al., 1997). Since very little is known about the
subcellular localization of Bax under growth-factor
receptor-mediated apoptosis in colorectal carcinoma
cells, we next explored the distribution of Bax in DiFi
cells triggered to undergo apoptosis by the inhibition of
EGFR. DiFi cells were treated with mAb 225 for
varying lengths of time, soluble and membrane-bound
fractions were prepared from the cytosolic and nuclear
departments, and immunoblotted with an anti-Bax Ab
or with an unrelated anti-Ku80 mAb (Figure 4B).
Results in Figure 4A demonstrated that mAb 225-
induced Bax exists predominantly in the soluble form
in both the cytosolic and, to a lesser extent, the nuclear
compartments. The nuclear accumulation of Bax
increased over a period of 24 h. The loss of soluble
nuclear Bax at 48 h after mAb225 treatment was
accompanied by an increase in the membrane-bound
form (Figure 4C, lane 10). Quantitation of Bax
expression indicated that about 29 – 37% of total
Figure 3 MAb 225 induces expression of Bax. (A) DiFi cells in culture were treated with 20 nM mAb 225 for the indicated times.
Cell extracts (30 mg protein) were analysed by SDS–PAGE and immunoblotted with an anti-Bax Ab (lower panel). As an internal
control, the upper portion of the Bax blot was blotted with an unrelated anti-HSP70 mAb (upper panel). (B) Ratios of HSP-70 to
Bax bands are presented in the lower panel. (C) DiFi cells were treated with (+) or without (7) 20 nM mAb 225 for the indicated
times and metabolically labeled with 35S-methionine for the final 3 h. Lysates containing equal amount of TCA perceptible c.p.m.
were immunoprecipitated with an anti-Bax Ab and analysed by SDS–PAGE. (D) DiFi cells were treated with mAb 225 with or
without 30 mg cycloheximide (CHX) per ml for 16 h. Cell lysates were assayed for the induction of apoptosis. The induction of Bax
was observed in five separate experiments
Figure 4 MAb 225 triggers nuclear translocation of Bax in
colorectal carcinoma DiFi cells. (A) DiFi cells were treated with
20 nM mAb 225 for the indicated times, and subjected to the
subcellular fractionation as described in the Materials and
methods. Soluble cytosolic and nuclear fractions were analysed
by SDS–PAGE and immunoblotted with an anti-Bax Ab. Lane
11, Bax positive control. The lower panel is an overexposed
autorad of the upper panel. (B) Cell lysates from the above
experiment was immunoblotted with an unrelated anti-Ku80 Ab.
(C) Membranes from the cytosol and nuclear fraction were
solubilized and analysed by SDS–PAGE and immunoblotted
with an anti-Bax Ab. The purity of the nuclear and cytosolic
extracts was confirmed by immunoblotting the control extracts
with nuclear enzyme PARP or cytosolic Caspase-3 (data not
shown). Similar results were obtained in three independent
experiments
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induced Bax was translocated to the nuclear compart-
ment in mAb 225-treated cells. Results in Figure 5A
indicate that the observed induction of proapoptotic
Bax protein was not a restricted eect of mAb 225 in
DiFi cells, as mAb 225 could eectively induce and
translocate Bax in FET cells which were also sensitive
to apoptosis by mAb 225. The purity of the
cytoplasmic and nuclear fraction was routinely
determined by immunoblotting the control extracts
with the nuclear proteins such as DNA-PK or PARP,
and with cytoplasmic protein such as CPP32 (Figure
5C). To further explore the generality of our finding,
we next examined the eect of butyrate, a physiological
relevant molecule in colonic epithelial cells (Cumming,
1981), and known to induce apoptosis in DiFi cells
(Mandal et al., 1997), on the expression of Bax. As
illustrated in Figure 6, butyrate induced the expression
of Bax as early as 6 h post-treatment, and this was
accompanied by subsequent increase in the Bax
accumulation in the nuclear compartment and subse-
quently (Panel A), to the nuclear membranes (Panels
B).
To further characterize the subcellular localization
of Bax in mAb 225-treated cells, we next examined the
Figure 5 MAb 225 induces the expression of Bax and its
translocation to the nucleus in colorectal carcinoma FET cells.
(A) cells were treated with 20 nM mAb 225 for the indicated
times, and subjected to the subcellular fractionation as described
in the Materials and methods. Soluble cytosolic and nuclear
fractions were analysed by SDS–PAGE and immunoblotted
with an anti-Bax Ab. Lower panel, Membranes from the cytosol
and nuclear fraction were solubilized and analysed by SDS–
PAGE and immunoblotted with an anti-Bax Ab. (B) Cell
lysates from the above experiment was immunoblotted with an
unrelated anti-Ku80 Ab. (C) The purity of the nuclear and
cytosolic extracts was confirmed by immunoblotting the control
extracts with antibodies against nuclear enzymes such as PARP
or DNA-PK, and cytosolic CPP32. Similar results were
obtained in two times
Figure 6 Butyrate induces and triggers nuclear translocation of
Bax in DiFi cells. (A) Cells were treated with 3 mM butyrate for
the indicated times, and subjected to the subcellular fractionation
as described in the Materials and methods. Soluble cytosolic and
nuclear fractions were analysed by SDS–PAGE and immuno-
blotted with an anti-Bax Ab. The lower panel is an overexposed
autorad of the upper panel. (B) Membranes from the cytosol and
nuclear fraction were solubilized and analysed by SDS–PAGE
and immunoblotted with an anti-Bax Ab. These experiments were
repeated two times with similar results
CON                                      mAb 225
Figure 7 Subcellular localization of Bax by immunofluorescence
and confocal imaging. (A and B) Immunofluorescence. (A) Bax-
staining (red) in control, untreated DiFi cells. (B) Bax-staining in
DiFi cells treated with 20 nM mAb 225 for 6 h. Arrows, Bax;
Arrowheads, nuclear membrane blebbing. (C and D) confocal
imaging. DiFi cells were treated with 30 nM mAb 225 (Panels D
and D') or without mAb (Panels C and C') for 12 h. White
arrows, Bax; and black arrows, Bax location in the same field
under transmission mode. Note that treatment of DiFi cells with
mAb 225 resulted in the nuclear immunostaining of Bax
(compare panel D with panel C). These experiments were
repeated two times
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redistribution of the Bax protein by indirect immuno-
fluorescence. For identification of nuclei, we used the
DNA intercalating agent DAPi (blue staining). The
Bax protein was detected using a TRITC-coupled
secondary antibody against the polyclonal anti-Bax
antibody (red staining). The Bax protein was primarily
localized in the cytoplasm in DiFi cells (Figure 7A).
The observed Bax staining was specific, as prior
incubation of anti-Bax Ab with the peptide against
which it was raised, completely blocked Bax-associated
immunofluorescence and incubation with the secondary
antibody alone showed a very low background (data
not shown). Following the apoptotic signal, Bax
translocated around the nucleus as shown by its
intense perinuclear accumulation except at the points
of nuclear membrane blebbing (Figure 7B). To confirm
the results of immunofluorescence studies, we next
examined the eect of mAb 225 on the distribution of
Bax in DiFi cells by confocal microscopy. The results
in Figure 7C demonstrate that Bax was primarily
localized in the cytosol in DiFi (Panel C is the
corresponding transmitted mode photograph). In
mAb 225-treated DiFi cells, the Bax-immunostaining
was intensely localized both around and inside (shown
by white arrows in Panel D) the nucleus. Taken
together, our results demonstrated that mAb 225-
induced apoptosis was accompanied by alteration in
the subcellular distribution of Bax.
Eect of mAb 225 on the expression and subcellular
localization of p53
Since Bax has been shown to be induced by p53, we
next examined whether the observed induction of Bax
in mAb 225-treated DiFi cells was dependent on p53.
As shown in Figure 8A, there was no induction of p53
by mAb 225, and the levels of p53 were actually
reduced in 225-treated cells. Data in Figure 8B
illustratate that DiFi cells have both wild-type and
mutated p53 as mAbs specific for total p53 (D0-1
mAb, lanes 1 and 2) and mutated p53 (240 mAb, lanes
3 and 4) eectively immunoprecipitated p53 from 35S-
labeled cell extracts. Similar results were obtained when
unlabeled cell extracts were immunoblotted with anti-
p53 mAbs after immunoprecipitation with DO-1 or 240
mAbs (data not shown). The data in Figure 8B also
confirmed that mAb 225-treatment reduced the levels
of p53 (Figure 8A). To understand the basis of the
reduced levels of p53 in mAb 225-treated cells, we
hypothesized that mAb 225-induced apoptosis may
involve redistribution of subcellular localization of p53.
Next, we examined the distribution of p53 in soluble
and membrane fractions prepared from the cytosolic
and nuclear compartments. Soluble p53 was found
localized primarily in the nucleus with some cytosolic
localization, and mAb 225 treatment resulted in a
modest time-dependent decrease in the levels of soluble
Figure 8 Eect of mAb 225 on the expression and subcellular localization of p53. (A) DiFi cells were treated with 20 nM mAb 225
for 24 h (lane 3), 12 h (lane 2), or 0 h (lane 1), and cell extracts were analysed by SDS–PAGE and immunoblotted with an anti-p53
mAb (clone DO-1) that recognizes the total (wild-type and mutated) p53. The DO-1 mAb used here immunoreacted with an
additional lower band in DiFi cell extract (lane 4) compared to positive control (lane 5). (B) Lysates from DiFi cells metabolically
labeled with 35S-methionine and treated with (+) or without (7) 20 nM mAb 225 were immunoprecipitated with either anti-p53 D0-
1 mAb (lanes 1 and 2) or anti-p53 240 mAb (lanes 3 and 4) and analysed by SDS–PAGE. An autoradiograph of a dried gel is
shown here. (C) DiFi cells were treated with 20 nM mAb 225 for the indicated times, and subjected to the subcellular fractionation
as described in the Materials and methods. Soluble cytosolic and nuclear fractions were analysed by SDS–PAGE and
immunoblotted with an anti-p53 mAb DO-1. Lower panel, cell lysates from the above experiment were immunoblotted with an
unrelated anti-Ku80 Ab. (D) Crude membranes from the cytosol and nuclear fraction were solubilized by SDS–PAGE and
immunoblotted with an anti-p53 mAb D0-1. Results shown were repeated three times
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p53 in both cytosolic and nuclear fractions (Figure
8C). In contrast, there was a significant time-dependent
increase in the levels of membrane-bound p53 in the
nuclei of mAb-treated cells (Figure 8D). Studies of p53
localization have shown it to be present in both the
cytosol and the nucleus, and translocation both inside
and outside of the nucleus can occur following dierent
stimuli (Ostermeyer et al., 1996; Middeler et al., 1997).
Comparison of the kinetics of p53 translocation with
that of newly synthesized Bax in mAb 225-treated cells
(Figure 3B) indicated that induction of Bax was an
early eect and p53 translocation was a late response
of mAb 225. In brief, although mAb 225-treatment did
not induce increased p53 expression, it is possible that
the observed redistribution of p53 from the soluble
cytosolic form to the nucleus could constitute an
apoptotic signal.
Discussion
To understand the mechanism of EGFR-induced
apoptosis in human colorectal carcinoma cells, we
investigated the eect of inhibition of EGFR-signaling
by mAb 225 in DiFi and FET cells by examining the
role of Bax pathway. It was observed that mAb 225-
induced apoptosis was accompanied by the induction
of expression of newly synthesized Bax. The mechan-
ism of observed induction of increased Bax protein
remains to be delineated. This may occur at the
transcriptional level and/or post-transcriptional level
and may involve enhanced stability of Bax protein.
Our finding that mAb 225-mediated apoptosis in DiFi
cells was accompanied by alteration in the subcellular
distribution of Bax, is important, as it suggests that
Bax redistribution may play a role in apoptosis. We
have demonstrated that Bax is predominantly localized
in the cytoplasm, but following the inhibition of
EGFR-signaling by mAb 225, it translocates to the
nucleus and subsequently to the nuclear membrane.
This finding is in agreement with a recent report by
Hsu et al. (1997) (who reported their results while this
study was in progress), demonstrating the cytosolic-to-
membrane redistribution of Bax during dexamethasone
or gamma-irradiation-induced apoptosis in murine
thymocytes. Furthermore, in addition to biochemical
methods of cell fractionation, we have also used
double-immunofluorescence and confocal microscopic
methods to document the in situ localization of Bax.
We have now demonstrated that following an
apoptotic signal, a significant amount of Bax
accumulates both inside and around the nucleus. The
observed induction expression of Bax and its
translocation to the nucleus during apoptosis was not
an event limited to DiFi cells, as induction of apoptosis
in FET cells by mAb 225 or induction of apoptosis in
DiFi cells by butyrate (a physiological relevant
molecule in colonic epithelial cells) was also accom-
panied by increased expression and redistribution of
Bax to the nucleus. At the moment, we do not know
the physiological significance of our finding. In this
context, it is important to note that on the basis of
structural similarity between the alpha-helical models
of Bcl-XL and diphtheria toxin, it has been proposed
that Bcl-XL and its family members may be involved in
regulating the ion-channels across membranes (Much-
more et al., 1996; Schendel et al., 1997). In the same
vein, it is possible that the observed intense localization
of Bax around the nucleus may influence the ion-
channels across the nuclear membrane in a manner
that promotes apoptosis.
Another notable finding in this study was the
redistribution of p53 from the soluble to the membrane
bound form in the nucleus during apoptosis. Our results
showed that the increased expression of Bax in mAb
225-treated DiFi cells was not related to enhanced
expression of p53. In contrast, there was a time-
dependent-decrease in the level of soluble p53. Inspite
of the fact that p53 is a nuclear protein, there is
considerable evidence that it also is present in the
cytosol, and that p53 can be translocated both inside
and outside of the nucleus following dierent stimuli
(Ostermeyer et al., 1996; Middeler et al., 1997). It also
has been shown that mutant p53 accumulates in the
nucleus and wild-type p53 translocates to the nucleus.
Since DiFi cells have both wild-type and mutant p53
(Figure 5B), it is possible that the observed transloca-
tion of p53 from the cytosol to the nucleus may be due
to wild-type p53. The possible role of the observed
redistribution of p53 from the soluble to the membrane
bound and its potential role in mAb 225-mediated
apoptosis remains to be established.
Data from the literature indicated that Bax lacks the
nuclear localization sequence but has a putative
carboxyl-terminal transmembrane region (Oltvai et
al., 1993), implying that it has the potential to insert
into membranes as demonstrated here in DiFi cells
undergoing apoptosis following blockade of EGF
receptor tyrosine kinase. Taken together our observa-
tions raise new questions: (i) why Bax exists in the
soluble form, inspite of the presence of a c-terminal
hydrophobic region; (ii) how Bax translocates to the
nucleus; and (iii) whether Bax redistribution depends
on its phosphorylation status or on the phosphoryla-
tion of other proteins. Regardless of the mechanism of
Bax redistribution, our results presented here have
clearly demonstrated that induction of apoptosis in
human colorectal carcinoma cells by either inhibition
of EGFR function or butyrate may involve the
subcellular redistribution of Bax in human colorectal
carcinoma cells.
Materials and methods
Cell cultures, cell extracts and immunoblotting
Human colorectal carcinoma DiFi cells (Olive et al., 1993;
Wu et al., 1995; Mandal et al., 1997; Mandel and Kumar,
1997) and FET cells (Huang et al., 1992) were maintained
in DMEM-F12 (1 : 1) supplemented with 10% fetal calf
serum. All experiments were performed with cells in
logarithmic phase by controling the plating density. Cell
lysates (30 mg protein) were resolved on a 7% or 10%
SDS – PAGE followed by probing with the desired
antibodies, and immune complexes were detected by using
an ECL method. The Bax antibody and its peptide were
obtained from the Santa Cruz. Anti-p53 mAbs (DO-1 and
240) were obtained from the Neomarkers.
Metabolic labeling with 35S-methionine
An equal number of cells were treated with or without
mAb 225 for varying periods of time, followed by
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metabolic labeling with 100 mCi/ml 35S-methionine in
methionine-free medium containing 2% FBS during the
last 3 h of culture. Cell extracts containing an equal
amount of total trichloroacetic acid perceptible counts
were immunoprecipitated with the desired mAb, resolved
on a SDS-polyacrylamide gel, and analysed by autoradio-
graphy (Kumar et al., 1991; Fan et al., 1993).
Apoptosis assays
Apoptotic cell death was quantitated by an ELISA assay
(Boehringer) that measures cytoplasmic histone-bound
DNA fragments (mono- and oligonucleosomes) generated
during apoptotic DNA fragmentation, and not free histone
or DNA that could be released during nonapoptotic cell
death (Mandal and Kumar, 1996; Mandal et al., 1997;
Leist et al., 1997; Szabo et al., 1997; Dimmeler et al.,
1997). After the desired treatment, cytoplasmic extracts
were made from both floating and attached cells according
to the manufacturer’s protocol. Briefly, wells were first
coated with anti-histone antibody, loaded with cytoplasmic
extracts, and followed by incubation with anti-DNA
second antibody conjugated with peroxidase. The amount
of peroxidase retained in the immunocomplex was
determined photometrically with 2,2'-azino-di-(3-ethyl-
benzthiazoline sulfonate) as a substrate.
DNA fragmentation assay
For DNA fragmentation assay, low molecular weight DNA
was isolated. Briefly, cells (36106/plate) were seeded in
100 mm plates, and treated as desired. Both floating and
attached cells were scraped and collected in media, washed
36 with PBS, and resuspended in 1 ml of lysis buer
(20 mM Tris-HCl, pH 8; 10 mM EDTA, pH 8; and 0.5%
Triton X-100). After 30 min incubation on ice, the lysates
were centrifuged at 12 000 r.p.m. (Eppendorf) for 10 min.
Low molecular weight DNA in the supernatant was
extracted with an equal volume of phenol/chloroform for
1 h at 48C. Ammonium acetate (2 M) was added to the
aqueous phase and DNA was precipitated with 2 vol of
ethanol at 7208C overnight. DNA was treated with RNase
A (1 mg/ml) at 378C for 1 h and total DNA was analysed
using 1.5% agarose gel, and visualized by ethidium
bromide staining of gel (Mandal et al., 1996).
Cell cycle analysis
The percentage of cells in dierent phases of the cell cycle
will be determined by staining with propidium iodide
(Sigma) and passed through the beam of an argon ion laser
turned to 514 (FAC/Scan; Becton Dickinson) as described
(Mandal and Kumar, 1997).
Subcellular fractionation
Cytosolic and nuclear extracts were prepared as described
(Kumar and Korutla, 1995; Mandal et al., 1996). Briefly,
cells were washed with phosphate-buered saline, and
pelleted by centrifugation. Cells were incubated on ice for
15 min in hypotonic buer A (10 mM HEPES [pH 7.9],
10 mM KCl, 1.5 mM MgCl2, 0.5 mM dithiothreitol, 0.5 mM
PMSF, 1 mM sodium vanadate, 1 mM sodium fluoride) and
homogenized in a loose fitting glass homogenizer with 15
strokes. Nuclei were separated from the cytosolic fraction
by centrifugation at 5000 r.p.m. for 5 min at 48C. The
cytosolic fraction was centrifuged at 40 000 r.p.m. for
30 min to pellet the crude membranes. Nuclei were washed
and resuspended in buer (20 mM HEPES [pH 7.9], 0.4 M
NaCl, 1 mM EDTA, 1 mM EGDA, 25% glycerol, 1 mM
dithiothreitol, 0.5 mM PMSF, 1 mM sodium vanadate,
1 mM sodium fluoride), lysed with vigorously shaking for
20 min, and centrifuged at 15 000 r.p.m. for 30 min to
collect the soluble nuclear fraction. Crude cytosolic and
nuclear membranes were resuspended in a volume of lysis
buer equal to that used to resuspend the cells and nuclei.
The purity of the nuclear and cytoplasmic extracts was
assessed by immunoblotting the control extracts with
mAbs against the nuclear enzymes such as PARP and
DNA-PK, or against CPP-32 which is predominantly
localized in the cytoplasm (Krajewska et al., 1997;
Posmantur et al., 1997; Krajewski et al., 1997).
Immunofluorescence and confocal studies
Cellular localization of Bax and p53 was determined using
indirect immunofluorescence (Martin et al., 1987) with
some modifications (Bandyopadhyay et al., 1998). Briefly,
cells grown on glass coverslips were fixed in methanol at
7208C for 10 min. Several dilutions of each antibody were
used to obtain the optimal results. DNA was stained with
DAPi (blue). For staining of Bax, DiFi cells were treated
with anti-Bax antibody followed by TRITC-labeled
secondary antibody (Molecular Probes). For controls,
cells were treated only with secondary antibody, omitting
the primary antibody, and no signals were detected. In
addition, no signals were observed after addition of the
anti-Bax antibody in the presence of Bax peptide. Confocal
microscopy was performed using a Zeiss laser scanning
confocal microscope. Each image represents Z-sections at
the same cellular level and magnification. In some of the
cases shown here, the transmission mode was also used on
the same microscopic field to visualize the entire cell.
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